Lectines liant le mannose : Questions médicales fréquentes
Nom anglais: Mannose-Binding Lectins
Descriptor UI:D037241
Tree Number:D12.776.503.311
Termes MeSH sélectionnés :
Early Detection of Cancer
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Lectines liant le mannose : Questions médicales les plus fréquentes",
"headline": "Lectines liant le mannose : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Lectines liant le mannose : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-13",
"dateModified": "2025-03-10",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Lectines liant le mannose"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Lectines",
"url": "https://questionsmedicales.fr/mesh/D037102",
"about": {
"@type": "MedicalCondition",
"name": "Lectines",
"code": {
"@type": "MedicalCode",
"code": "D037102",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.503"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Lectine liant le mannose",
"alternateName": "Mannose-Binding Lectin",
"url": "https://questionsmedicales.fr/mesh/D037601",
"about": {
"@type": "MedicalCondition",
"name": "Lectine liant le mannose",
"code": {
"@type": "MedicalCode",
"code": "D037601",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.503.311.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Lectines liant le mannose",
"alternateName": "Mannose-Binding Lectins",
"code": {
"@type": "MedicalCode",
"code": "D037241",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jatinder Singh",
"url": "https://questionsmedicales.fr/author/Jatinder%20Singh",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Biology and Biochemistry, Guru Nanak Dev University, Amritsar, India."
}
},
{
"@type": "Person",
"name": "Manpreet Kaur",
"url": "https://questionsmedicales.fr/author/Manpreet%20Kaur",
"affiliation": {
"@type": "Organization",
"name": "Department of Human Genetics, Guru Nanak Dev University, Amritsar, India."
}
},
{
"@type": "Person",
"name": "Namarta Kalia",
"url": "https://questionsmedicales.fr/author/Namarta%20Kalia",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Biology and Biochemistry, Guru Nanak Dev University, Amritsar, India."
}
},
{
"@type": "Person",
"name": "Kárita Cláudia Freitas Lidani",
"url": "https://questionsmedicales.fr/author/K%C3%A1rita%20Cl%C3%A1udia%20Freitas%20Lidani",
"affiliation": {
"@type": "Organization",
"name": "Laboratory of Molecular Immunopathology, Clinical Hospital, Federal University of Paraná, Curitiba, Brazil."
}
},
{
"@type": "Person",
"name": "Fabiana Antunes Andrade",
"url": "https://questionsmedicales.fr/author/Fabiana%20Antunes%20Andrade",
"affiliation": {
"@type": "Organization",
"name": "Laboratory of Molecular Immunopathology, Clinical Hospital, Federal University of Paraná, Curitiba, Brazil."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Modelled mortality benefits of multi-cancer early detection screening in England.",
"datePublished": "2023-04-25",
"url": "https://questionsmedicales.fr/article/37185463",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41416-023-02243-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of early detection on cancer curability: A modified Delphi panel study.",
"datePublished": "2022-12-21",
"url": "https://questionsmedicales.fr/article/36542647",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0279227"
}
},
{
"@type": "ScholarlyArticle",
"name": "Advances in microRNAs as Emerging Biomarkers for Colorectal Cancer Early Detection and Diagnosis.",
"datePublished": "2024-10-15",
"url": "https://questionsmedicales.fr/article/39456841",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms252011060"
}
},
{
"@type": "ScholarlyArticle",
"name": "REPRESENT recommendations: improving inclusion and trust in cancer early detection research.",
"datePublished": "2023-09-09",
"url": "https://questionsmedicales.fr/article/37689805",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41416-023-02414-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "Evaluation of cell-free DNA approaches for multi-cancer early detection.",
"datePublished": "2022-11-17",
"url": "https://questionsmedicales.fr/article/36400018",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ccell.2022.10.022"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Lectines",
"item": "https://questionsmedicales.fr/mesh/D037102"
},
{
"@type": "ListItem",
"position": 5,
"name": "Lectines liant le mannose",
"item": "https://questionsmedicales.fr/mesh/D037241"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Lectines liant le mannose - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Lectines liant le mannose",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-14",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Lectines liant le mannose",
"description": "Comment diagnostiquer une déficience en lectines liant le mannose ?\nQuels tests sont utilisés pour évaluer les lectines ?\nLes niveaux de lectines peuvent-ils varier ?\nQuels symptômes peuvent indiquer un problème avec les lectines ?\nPeut-on mesurer les lectines dans d'autres fluides ?",
"url": "https://questionsmedicales.fr/mesh/D037241?mesh_terms=Early+Detection+of+Cancer&page=5#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Lectines liant le mannose",
"description": "Quels symptômes sont associés à une déficience en lectines ?\nLes symptômes varient-ils selon l'âge ?\nY a-t-il des signes cutanés associés ?\nLes symptômes sont-ils toujours visibles ?\nLes symptômes peuvent-ils s'aggraver avec le temps ?",
"url": "https://questionsmedicales.fr/mesh/D037241?mesh_terms=Early+Detection+of+Cancer&page=5#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Lectines liant le mannose",
"description": "Comment prévenir les infections chez les patients déficients ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nLes exercices physiques sont-ils bénéfiques ?\nY a-t-il des mesures spécifiques à prendre ?\nLes consultations médicales régulières sont-elles importantes ?",
"url": "https://questionsmedicales.fr/mesh/D037241?mesh_terms=Early+Detection+of+Cancer&page=5#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Lectines liant le mannose",
"description": "Quels traitements sont disponibles pour les déficiences en lectines ?\nLes suppléments peuvent-ils aider ?\nLa vaccination est-elle recommandée ?\nY a-t-il des traitements expérimentaux ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D037241?mesh_terms=Early+Detection+of+Cancer&page=5#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Lectines liant le mannose",
"description": "Quelles complications peuvent survenir avec une déficience en lectines ?\nLes infections peuvent-elles être mortelles ?\nY a-t-il un risque accru de cancer ?\nLes complications sont-elles réversibles ?\nComment surveiller les complications ?",
"url": "https://questionsmedicales.fr/mesh/D037241?mesh_terms=Early+Detection+of+Cancer&page=5#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Lectines liant le mannose",
"description": "Quels sont les facteurs de risque pour les déficiences en lectines ?\nL'âge influence-t-il le risque ?\nLes maladies auto-immunes augmentent-elles le risque ?\nLe mode de vie affecte-t-il le risque ?\nLes infections chroniques sont-elles un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D037241?mesh_terms=Early+Detection+of+Cancer&page=5#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en lectines liant le mannose ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins peuvent mesurer les niveaux de lectines et évaluer la fonction immunitaire."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer les lectines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests d'immunoessai et les dosages enzymatiques sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les niveaux de lectines peuvent-ils varier ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les niveaux de lectines peuvent fluctuer en fonction de l'état de santé et des infections."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec les lectines ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des infections récurrentes ou des maladies auto-immunes peuvent signaler un dysfonctionnement."
}
},
{
"@type": "Question",
"name": "Peut-on mesurer les lectines dans d'autres fluides ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les lectines peuvent également être mesurées dans les fluides corporels comme la salive."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à une déficience en lectines ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des infections fréquentes, des allergies et des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent se manifester différemment chez les enfants et les adultes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cutanés associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées peuvent survenir en raison de réactions immunitaires anormales."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils toujours visibles ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certains patients peuvent être asymptomatiques malgré une déficience en lectines."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils s'aggraver avec le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, sans traitement, les symptômes peuvent devenir plus graves et fréquents."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections chez les patients déficients ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une bonne hygiène, des vaccinations et un suivi médical régulier sont essentiels."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans la prévention ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation équilibrée peut renforcer le système immunitaire et la santé globale."
}
},
{
"@type": "Question",
"name": "Les exercices physiques sont-ils bénéfiques ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut améliorer la santé immunitaire et réduire le stress."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures spécifiques à prendre ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les foules et se laver les mains fréquemment sont des mesures préventives clés."
}
},
{
"@type": "Question",
"name": "Les consultations médicales régulières sont-elles importantes ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des consultations régulières permettent de surveiller la santé et d'ajuster les traitements."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les déficiences en lectines ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des thérapies immunomodulatrices et des antibiotiques préventifs."
}
},
{
"@type": "Question",
"name": "Les suppléments peuvent-ils aider ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suppléments nutritionnels peuvent soutenir le système immunitaire, mais pas spécifiquement les lectines."
}
},
{
"@type": "Question",
"name": "La vaccination est-elle recommandée ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations peuvent aider à prévenir les infections chez les patients à risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours sur des thérapies géniques et des traitements ciblés."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction des besoins individuels du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une déficience en lectines ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des infections graves, des maladies auto-immunes et des allergies."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles être mortelles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections peuvent être fatales si elles ne sont pas traitées rapidement."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de cancer ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent un risque accru de cancer chez les patients immunodéprimés."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent causer des dommages permanents."
}
},
{
"@type": "Question",
"name": "Comment surveiller les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens réguliers et des tests de laboratoire aident à surveiller les complications potentielles."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les déficiences en lectines ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux, les infections fréquentes et certaines maladies génétiques sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les jeunes enfants et les personnes âgées sont plus susceptibles de présenter des déficiences."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes augmentent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes atteintes de maladies auto-immunes peuvent avoir un risque accru de déficiences."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie malsain, comme le tabagisme, peut augmenter le risque de déficiences immunitaires."
}
},
{
"@type": "Question",
"name": "Les infections chroniques sont-elles un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les infections chroniques peuvent affaiblir le système immunitaire et augmenter le risque."
}
}
]
}
]
}
Screening programmes utilising blood-based multi-cancer early detection (MCED) tests, which can detect a shared cancer signal from any site in the body with a single, low false-positive rate, could re...
A natural history ('interception') model of cancer was previously used to characterise potential benefits of MCED screening (based on published performance of an MCED test). We built upon this using a...
Estimated late-stage and mortality reductions were robust to a range of assumptions. With the least favourable dwell (sojourn) time and cfDNA status hazard ratio assumptions, we estimated, among 100,0...
Realising the potential benefits of MCED tests could substantially reduce late-stage cancer diagnoses and mortality....
Expert consensus on the potential benefits of early cancer detection does not exist for most cancer types. We convened 10 practicing oncologists using a RAND/UCLA modified Delphi panel to evaluate whi...
Colorectal cancer (CRC) remains the second most common cause of cancer-related mortality worldwide, necessitating advancements in early detection and innovative treatment strategies. MicroRNAs (miRNAs...
Detecting cancer early is essential to improving cancer outcomes. Minoritized groups remain underrepresented in early detection cancer research, which means that findings and interventions are not gen...
In the Circulating Cell-free Genome Atlas (NCT02889978) substudy 1, we evaluate several approaches for a circulating cell-free DNA (cfDNA)-based multi-cancer early detection (MCED) test by defining cl...
Globally, among all women, the most frequently detected and diagnosed and the most lethal type of cancer is breast cancer (BC). In particular, bone is one of the most frequent distant metastases 24in ...
GSE55715, GSE103357, and GSE146661 gene expression profiling data were downloaded from the GEO database. There was 14 breast cancer with bone metastasis samples and 8 breast cancer tissue samples. GEO...
By GO enrichment analysis, 143 DEGs were enriched in the following GO terms: extracellular structure organization, extracellular matrix organization, leukocyte migration class II protein complex, coll...
2 abnormally expressed hub genes could play a pivotal role in the breast cancer with bone metastasis by affecting bone homeostasis imbalance in the bone microenvironment....
Seemingly normal tissues progressively become populated by mutant clones over time. Most of these clones bear mutations in well-known cancer genes but only rarely do they transform into cancer. This p...
We analyzed recent mutational screens of healthy and cancer-free diseased tissues to compare somatic drivers and the causes of somatic variation across tissues. We then reviewed the mechanisms of clon...
The extent of somatic variation is highly variable across tissues and depends on intrinsic features, such as tissue architecture and turnover, as well as the exposure to endogenous and exogenous insul...
Somatic variation and the factors governing homeostasis of normal tissues should be taken into account when devising strategies for cancer prevention and early detection....
The summary presented herein covers recommendations on the early detection of prostate cancer and provides a framework to facilitate clinical decision-making in the implementation of prostate cancer s...
The systematic review utilized to inform this guideline was conducted by an independent methodological consultant. The systematic review was based on searches in Ovid MEDLINE and Embase and Cochrane D...
The Early Detection of Prostate Cancer Panel developed evidence- and consensus-based guideline statements to provide guidance in prostate cancer screening, initial and repeat biopsy, and biopsy techni...
Prostate-specific antigen (PSA)-based prostate cancer screening in combination with shared decision-making (SDM) is recommended. Current data regarding risk from population-based cohorts provide a bas...
Lung cancer is a major global health concern with a low survival rate, often due to late-stage diagnosis. Liquid biopsy offers a non-invasive approach to cancer detection and monitoring, utilizing var...
The present study is a systematic review of the evaluation of screening programs as a strategy for early detection of oral cancer. The aim of this study was to assess whether screening through visual ...